IMPACT Therapeutics licenses senaparib to Pharmanovia for Europe, Middle East and North Africa, Australia and New Zealand

The territory includes the Middle East and North Africa as a region; no individual African country is named in the release text available to this run, so the African nexus is regional only.


Coverage: The Meridian legal market record (editorial).

The territory includes the Middle East and North Africa as a region; no individual African country is named in the release text available to this run, so the African nexus is regional only.

Record ID TX-AFR-2026-0023
Record type Commercial IP transaction
Transaction type Patent licence, Exclusive licence, In-licensing
IP rights patent, regulatory data
Status Signed
Qualifying date 2026-07-31
Sector Life sciences · Pharmaceuticals – oncology
African markets Multi-jurisdictional
Licensed territory Europe, Middle East and North Africa, Australia and New Zealand.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • IMPACT Therapeutics (China): licensor
  • Pharmanovia (United Kingdom): licensee

Key terms

  • Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: Europe, Middle East and North Africa, Australia and New Zealand

Sources

  1. IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand, BioSpace (press release), 2026-07-31

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.